EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 18 / No 12 (Décembre 2002) Med Sci (Paris), 18 12 (2002) 1282-1286 References
Free Access
Issue
Med Sci (Paris)
Volume 18, Number 12, Décembre 2002
Page(s) 1282 - 1286
Section M/S Revues : Articles de Synthèse
DOI https://doi.org/10.1051/medsci/200218121282
Published online 15 December 2002
  1. Ring CJ. Cytolytic viruses as potential anti-cancer agents. J Gen Virol 2002; 83: 491–502. [Google Scholar]
  2. Norman KL, Farassati F, Lee PW. Oncolytic viruses and cancer therapy. Cytokine Growth Factor Rev 2001; 12: 271–82. [Google Scholar]
  3. Virgin HW, Tyler KL, Dermody TS. Reovirus. In: Nathanson N, ed. Viral pathogenesis. Philadelphia: Lippincott-Raven, 1996 : 669–99. [Google Scholar]
  4. Nibert ML, Schiff LA. Reoviruses and their replication. In : Knipe DM, Howley PM, eds. Fundamental virology, 4th ed. Philadelphia: Lippincott-Raven Publishers, 2001 : 793–842. [Google Scholar]
  5. Rosen L, Evans HE, Spickard A. Reovirus infections in human volunteers. Am J Hyg 1963; 77: 29–37. [Google Scholar]
  6. Organ EL, Rubin DH. Pathogenesis of reovirus gastrointestinal and hepatobiliary disease. Curr Top Microbiol Immunol 1998; 233 : 67–83. [Google Scholar]
  7. Bisaillon M, Bernier L, Sénéchal S, Lemay G. A glycosyl hydrolase activity of mammalian reovirus σ1 protein can contribute to viral infection through a mucus layer. J Mol Biol 1999; 286: 759–73. [Google Scholar]
  8. Danis C, Lemay G. Protein synthesis in different cell lines infected with orthoreovirus serotype 3: inhibition of host-cell protein synthesis correlates with accelerated viral multiplication and cell killing. Biochem Cell Biol 1993; 71: 81–5. [Google Scholar]
  9. Hashiro G, Loh PC, Yau JT. The preferential cytotoxicity of reovirus for certain transformed cell lines. Arch Virol 1977; 54: 307–15. [Google Scholar]
  10. Duncan MR, Stanish SM, Cox DC. Differential sensitivity of normal and transformed human cells to reovirus infection. J Virol 1978; 28: 444–9. [Google Scholar]
  11. Strong JE, Lee PWK. The verbB oncogene enhanced cellular susceptibility to reovirus infection. J Virol 1996; 70: 612–6. [Google Scholar]
  12. Strong JE, Coffey MC, Tang D, Sabinin P, Lee PW. The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus. EMBO J 1998; 17: 3351–62. [Google Scholar]
  13. Kaufman RJ. The double stranded RNA-activated protein kinase PKR. In : Sonenberg N, Hershey JWB, Mathews MB, eds. Translation control of gene expression. New York: Cold Spring Harbor Laboratory Press, 2000 : 503–27. [Google Scholar]
  14. Samuel CE. Reoviruses and the interferon system. Curr Top Microbiol Immunol 1998; 233 : 125–45. [Google Scholar]
  15. Schiff LA. Reovirus capsid proteins σ3 and µ1 : interactions that influence viral entry, assembly, and translational control. Curr Top Microbiol Immunol 1998; 233: 167–83. [Google Scholar]
  16. Gale M, Katze MG. Molecular mechanisms of interferon resistance mediated by viral-directed inhibition of PKR, the interferon-induced protein kinase. Pharmacol Ther 1998; 78: 29–46. [Google Scholar]
  17. Mundschau LJ, Faller DV. Oncogenic Ras induces an inhibitor of double stranded RNA-dependent eukaryotic initiation factor 2α-kinase activation.J Biol Chem 1992; 267: 23092–8. [Google Scholar]
  18. Mundschau LJ, Faller DV. Endogenous inhibitors of the dsRNA-dependent elF-2αprotein kinase PKR in normal and ras transformed cells. Biochimie 1994; 76: 792–800. [Google Scholar]
  19. Reuter CWM, Morgan MA, Bergmann L. Targeting the Ras signaling pathway: a rational mechanism-based treatment for hematologic malignancies. Blood 2000; 96: 1655–69. [Google Scholar]
  20. Coffey MC, Strong JE, Forsyth PA, Lee PW. Reovirus therapy of tumors with activated Ras pathway. Science 1998; 282: 1332–4. [Google Scholar]
  21. Wilcox ME, Yang WQ, Senger D, et al. Reovirus as an oncolytic agent against experimental human malignant gliomas. J Natl Cancer Inst 2001; 93: 903–12. [Google Scholar]
  22. Hirasawa K, Nishikawa SG, Norman KL, Alain T, Kossakowska A, Lee PW. Oncolytic reovirus against ovarian and colon cancer. Cancer Res 2002; 62: 1696–701. [Google Scholar]
  23. Norman KL, Coffey MC, Hirasawa K, et al. Reovirus oncolysis of human breast cancer. Hum Gene Ther 2002; 13: 641–52. [Google Scholar]
  24. Alain T, Hirasawa K, Pon KJ, et al. Reovirus therapy of lymphoid malignancies. Blood 2002 (PMID 12393565). [Google Scholar]
  25. Hirasawa K, Yoon CS, Nishikawa SG, Waisman DM, Lee PWK. Reovirus therapy of metastatic cancer models in immune-competent mice. Annual Meeting of the American Association for Cancer Research 2001. Résumé: http://aacr01.agora.com/ planner/displayabstract.as presentation, id=13225. [Google Scholar]
  26. Oberhaus SM, Dermody TS, Tyler KL. Apoptosis and the cytopathic effects of reovirus. Curr Top Microbiol Immunol 1998; 233 : 23–49. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.